New R&D Facility in Hungary will Double Annual Testing Capability
Go behind the scenes at Teva to Debrecen in Hungary, where a new $2.4 million R&D facility is helping to speed up production and get medicines to patients faster
Getting medicines to the patients who need them, quickly and efficiently, is key at Teva. Producing those medicines sustainably is also key. That’s why we’ve invested $2.4 million in a new state-of-the-art R&D facility at Debrecen, Hungary, which will allow it to double the number of tests it conducts each year.
This ability to move faster allows us to better serve the patients who rely on us every day. Teva has already invested over $1 million in its Hungarian operations, where we employ 2,000 people, 220 of whom work in R&D. The Debrecen site is one of Teva’s largest global R&D and manufacturing centers.
Over the last two years, Teva has invested $2 million+ in a new R&D lab in Debrecen
The revamped 5,000-square-foot biological testing laboratory will double the number of in vitro biological tests it conducts every year
The facility can accommodate up to 16 scientists who perform development tests for generic peptides and new development pipeline products
Scientists will also perform routine release and stability tests for Teva’s already marketed biological products
The new facility’s sustainable design will save on both energy and costs
Approximately one-third of the investment went towards new state-of-the-art equipment including instruments to accelerate test sample processing and increase efficiency
The new facility will run in vitro – meaning ‘within the glass’ – experiments that take place outside, rather than inside of living organisms, under controlled and regulated circumstances.
It will carry out two main functions:
- Participate in the research of new products for global markets, including formulations to treat pain and asthma, by testing samples from early development experiments as well as from preclinical and clinical trials
- Testing of biologics in bioassays (release, stability, characterization and support of development)
“Debrecen is a site of strategic importance that operates as a complex manufacturing and R&D center,” says Csaba Pogány, Senior Director Non Clinical Development & Regulatory Affairs for Teva Global R&D in Hungary. “The number of biological tests will be doubled, using state-of-the-art equipment and the expertise of our people.”
The new investment is an important indicator of Teva’s commitment to developing innovative and biosimilar medicines alongside its classical generics portfolio. A leading producer of generics medicines for over 100 years, Teva is now investing in next-generation bio-technology, using our knowledge of complex molecules to build a strong and growing portfolio of biologics.
“Biologicals are an important part of Teva’s pipeline, so it’s important to have modern facilities such as Debrecen’s where they can be tested in a regulated environment that adheres to current good laboratory and good manufacturing practices,” said Yael Marantz, who leads Non-Clinical Development at Teva. “This ensures appropriate conditions for the approval of new products and continuous testing later on.”
In addition to enhanced higher-speed testing facilities, the research center’s sustainable design will also save on energy and costs and reduce environmental impact.
Find out more
Read more about sustainability and a new eco campaign at Teva’s Debrecen facility
Find out about Teva’s one billion dollar investment in biologics
Meet Noa Anker, leading Teva's Active Pharmaceutical Ingredients (API) manufacturing and operations team